Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
- Partnership combines Protalix’s rare disease and biologics expertise with Secarna’s AI‑powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications
- Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization
Martinsried (Munich), Germany, and Carmiel, Israel, December 17, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide (ASO) therapies against multiple targets for rare renal indications.
Secarna Pharmaceuticals presents promising preclinical and translational data on proprietary antisense oligonucleotide SECN-15 at SITC 2025 Annual Meeting
- SECN-15 represents promising new therapeutic strategy to enhance anti-tumor immunity and overcome resistance to checkpoint inhibitors
- Preclinical data demonstrate strong anti-tumor efficacy in monotherapy as well as in combination therapy setting
- Translational data confirm gastric cancer as one of the lead indications for planned clinical Phase I/II trial
Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced that preclinical data for its proprietary antisense oligonucleotide (ASO) SECN-15 will be presented in a poster session at the 40th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD, USA, on Friday, November 7, 2025.
Secarna Pharmaceuticals enters into discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
- The companies will jointly develop a first-in-class disease-modifying oligonucleotide against a newly validated target relevant for rare genetic disorders as well as broader disease conditions
- Collaboration will leverage expertise and synergies of both companies’ platforms to bring new treatments to patients
Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the signing of an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases. The agreement covers the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform.
Would you like to keep up to date with the latest from Secarna Pharmaceuticals?
Click here to subscribe here to receive regular updates:
Latest News & Events
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
- Partnership combines Protalix’s rare disease and biologics expertise with Secarna’s AI‑powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications
- Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization
Martinsried (Munich), Germany, and Carmiel, Israel, December 17, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide (ASO) therapies against multiple targets for rare renal indications.
Secarna Pharmaceuticals presents promising preclinical and translational data on proprietary antisense oligonucleotide SECN-15 at SITC 2025 Annual Meeting
- SECN-15 represents promising new therapeutic strategy to enhance anti-tumor immunity and overcome resistance to checkpoint inhibitors
- Preclinical data demonstrate strong anti-tumor efficacy in monotherapy as well as in combination therapy setting
- Translational data confirm gastric cancer as one of the lead indications for planned clinical Phase I/II trial
Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced that preclinical data for its proprietary antisense oligonucleotide (ASO) SECN-15 will be presented in a poster session at the 40th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD, USA, on Friday, November 7, 2025.
Secarna Pharmaceuticals enters into discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
- The companies will jointly develop a first-in-class disease-modifying oligonucleotide against a newly validated target relevant for rare genetic disorders as well as broader disease conditions
- Collaboration will leverage expertise and synergies of both companies’ platforms to bring new treatments to patients
Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the signing of an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases. The agreement covers the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform.